Citations

Showing 10 of 108083 citations.

Impact of Rome IV criteria on the prevalence of post‐infection irritable bowel syndrome
Breen‐Lyles, Margaret K., Decuir, Marijke, Byale, Anjali , Smith, Kirk , Grover, Madhusudan , Breen-Lyles, Margaret

Mayo Clinic

Neurogastroenterology & Motility | January 12, 2023 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/nmo.14532 | PMID 36633303 Get It

AbstractBackgroundThe Rome IV irritable bowel syndrome (IBS) criteria include changes to the description and frequency of abdominal pain. Existing studies have demonstrated a lower prevalence and greater severity in IBS patients identified using Rome IV than Rome III criteria. Our aim was to investigate the prevalence of post‐infection IBS (PI‐IBS) using Rome IV criteria in a population‐based cohort of laboratory‐confirmed C. jejuni infection cases.MethodsThe Minnesota Department of Health (MDH) requires notification of Campylobacter cases and interviews patients to gather information on clinical symptoms. For this study, the Rome IV diagnostic questionnaire was utilized 6–9 months after infection to determine the development of PI‐IBS. The survey responses were analyzed for the prevalence of IBS and symptom severity.Key ResultsSurveys were completed by 391 participants (31% response rate). Twenty‐three patients had pre‐existing IBS, and 18 did not complete enough questions to categorize their case status. Of the 350 remaining participants, 58 (17%) met Rome IV criteria. An additional 47 patients would have met the Rome III IBS criteria for pain frequency, driving the cumulative prevalence to 30%. The mean IBS Symptom Severity Score (IBS‐SSS) in Rome IV patients was significantly higher than in Rome III (p < 0.05). With Rome IV, IBS‐diarrhea was the most common subtype.Conclusions & InferencesRome IV criteria resulted in a 19% lower prevalence of PI‐IBS than earlier reported Rome III‐based prevalence in a similar population. Rome IV defined PI‐IBS patients have greater symptom severity but similar distribution of IBS subtypes.
Evaluating the Need for Preoperative MRI Before Primary Hip Arthroscopy in Patients 40 Years and Younger With Femoroacetabular Impingement Syndrome: A Multicenter Comparative Analysis
Berrier, Ava S., Helm, J. Matthew , Koolmees, Dylan S. , Pareek, Ayoosh , Nwachukwu, Benedict U. , Ramkumar, Prem N. , Krych, Aaron J. , Makhni, Eric Chugh , Harris, Joshua D.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 12, 2023 | Volume: 11 | Issue: 1 | Pages: No page available

10.1177/23259671221144776 | PMID 36655021 Get It

Background: Routine hip magnetic resonance imaging (MRI) before arthroscopy for patients with femoroacetabular impingement syndrome (FAIS) offers questionable clinical benefit, delays surgery, and wastes resources. Purpose: To assess the clinical utility of preoperative hip MRI for patients aged ≤40 years who were undergoing primary hip arthroscopy and who had a history, physical examination findings, and radiographs concordant with FAIS. Study Design: Cohort study; Level of evidence, 3. Methods: Included were 1391 patients (mean age, 25.8 years; 63% female; mean body mass index, 25.6) who underwent hip arthroscopy between August 2015 and December 2021 by 1 of 4 fellowship-trained hip surgeons from 4 referral centers. Inclusion criteria were FAIS, primary surgery, and age ≤40 years. Exclusion criteria were MRI contraindication, reattempt of nonoperative management, and concomitant periacetabular osteotomy. Patients were stratified into those who were evaluated with preoperative MRI versus those without MRI. Those without MRI received an MRI before surgery without deviation from the established surgical plan. All preoperative MRI scans were compared with the office evaluation and intraoperative findings to assess agreement. Time from office to arthroscopy and/or MRI was recorded. MRI costs were calculated. Results: Of the study patients, 322 were not evaluated with MRI and 1069 were. MRI did not alter surgical or interoperative plans. Both groups had MRI findings demonstrating anterosuperior labral tears treated intraoperatively (99.8% repair, 0.2% debridement, and 0% reconstruction). Compared with patients who were evaluated with MRI and waited 63.0 ± 34.6 days, patients who were not evaluated with MRI underwent surgery 6.5 ± 18.7 days after preoperative MRI. MRI delayed surgery by 24.0 ± 5.3 days and cost a mean $2262 per patient. Conclusion: Preoperative MRI did not alter indications for primary hip arthroscopy in patients aged ≤40 years with a history, physical examination findings, and radiographs concordant with FAIS. Rather, MRI delayed surgery and wasted resources. Routine hip MRI acquisition for the younger population with primary FAIS with a typical presentation should be challenged.
Efficacy of collagenaseClostridium histolyticumin men with congenital penile curvature
Kulkarni, Yogesh , Pattillo, C, Stirland, Isaac , Flores, Ashley, Ziegelmann, Matthew , Köhler, Tobias , Trost, Landon , Helo, Sevann , Green, Benjamin

Mayo Clinic

The Journal of Sexual Medicine | January 12, 2023 | Volume: 20 | Issue: 2 | Pages: 194-199

10.1093/jsxmed/qdac006 | PMID 36763911 Get It

AbstractBackgroundCollagenase Clostridium histolyticum (CCH) has been proven effective in multiple subpopulations of PD men; however, no studies have evaluated its role with congenital penile curvature (CPC).AimTo evaluate the safety and efficacy of CCH in men with CPC.MethodsA prospective registry was queried of men undergoing CCH injections at our institution. Beginning in 2016, CCH was administered to CPC men using a similar protocol to PD. A comparative analysis was performed between cohorts to evaluate the safety and efficacy of therapy.OutcomesObjective measures included penile length and curvature, while subjective outcomes included standardized (International Index of Erectile Function and Peyronie’s Disease Questionnaire) and non-standardized assessments. Curvature outcomes were categorized as follows: 1 – included all men, with the most recent assessment considered final, and 2 – only men who had completed eight CCH injections or stopped early due to satisfaction.ResultsFrom 2014 to Oct 2021, a total of 453 men (408 PD, 45 CPC) underwent one or more CCH injections. In comparing cohorts, CPC men were younger (33 vs 58 years, p&lt;0.0001), had lesser baseline curvatures (52.5 vs 65°, p&lt;0.01), more ventral curves (25.7 vs 9.2%, p&lt;0.01), and longer penile lengths (12.5 vs 12.0 cm, p=0.04). Following treatment, both cohorts experienced similar curvature improvements. Specifically, PD men experienced 20-25° or 33-35% improvements depending on definition compared to 25-30° or 40-50% in CPC men (all p-values &gt;0.05). CPC and PD men also demonstrated similar changes on standardized questionnaires, with the exception of the Psychological and Physical subdomain, which was more improved in CPC men (-11 vs -4, p&lt;0.01). Baseline curvature was positively correlated with greater absolute (degree) and relative (percent) improvements. Adverse events were similar between groups after controlling for confounders.Clinical ImplicationsCCH may be safely and effectively administered in men with CPC. These data provide the first evidence for the efficacy of a non-surgical therapeutic option in this cohort.Strengths and LimitationsStrengths – large, prospective series with standardized assessments; Limitations - non-randomized study, short-term follow-up, and lack of standardized method to differentiate CPC from PD.ConclusionsCCH may be safely and effectively administered to men with CPC, with similar success rates compared to PD. Increasing curvature was associated with greater absolute (degree) and relative (percent) improvements, supporting the role for CCH in men with mild, moderate, or severe curvatures. External validation is warranted prior to routine implementation.
An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Donskov, Agnete Overgaard , Mackie, Sarah , Hauge, Ellen‐Margrethe , Gutiérrez, Carlos Enrique Toro , Hansen, Ib Tønder , Hemmig, Andrea Katharina , Maas, Aatke van der , Gheita, Tamer A. , Nielsen, Berit Dalsgaard , Douglas, Karen, Matteson, Eric L. , Matza, Mark , Ocampo, Vanessa , Grainger, Rebecca , Bran, Andrea, Appenzeller, Simone , Goecke, Annelise, Colmán, Nelly , Keen, Helen , Kuwana, Masataka , Gupta, Latika, Salim, Babur , Harifi, Ghita , Erraoui, M. , Ziadé, Nelly , Al-Ani, Nizar Abdulateef, Ajibade, Adeola , Frølund, Line L. , Yates, Max , Pimentel-Quiroz, Víctor R. , Lyrio, André Marun , Sandovici, Maria , Geest, Kornelis S. M. van der , Brouwer, Elisabeth , Dejaco, Christian , Keller, Kresten Krarup , Gupta, Latika , Mackie, Sarah Louise , Gheita, Tamer , Conway, Richard , Monti, Sara , Sattui, Sebastian E , Grainger, Rebecca , Keen, Helen , Kuwana, Masataka , Gupta, Latika , Ziade, Nelly , Knitza, Johannes , Pimentel-Quiroz, Victor R , Van der Geest, Kornelis S M , Dejaco, Christian , Keller, Kresten Krarup , Yates, Max , Conway, Richard , Rezuş, Elena , Dasgupta, Bhaskar , Monti, Sara , Sattui, Sebastian E. , Gromova, Margarita Aleksandrovna , Helliwell, Toby

Mayo Clinic

Rheumatology | January 12, 2023 | Volume: 62 | Issue: 8 | Pages: 2797-2805

10.1093/rheumatology/keac713 | PMID 36637182 Get It

Abstract Objectives To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR &gt;2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing &gt;25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials.
Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized PROMISE ‐2 trial
Starling, Amaal J. , Cowan, Robert P. , Buse, Dawn C. , Marmura, Michael J. , Hirman, Joe, Brevig, Thomas, Cady, Roger , Marmura, Michael J , Cowan, Robert P , Diener, Hans‐Christoph

Mayo Clinic

Headache: The Journal of Head and Face Pain | January 12, 2023 | Volume: 63 | Issue: 2 | Pages: 264-274

10.1111/head.14434 | PMID 36633219 Get It

Abstract Objective To evaluate the effect of eptinezumab on patient‐reported outcomes in patients with chronic migraine (CM) and medication‐overuse headache (MOH). Background MOH is a secondary headache disorder commonly occurring in patients with CM and associated with functional and psychological impairments. Medication overuse and monthly headache and migraine days were reduced with eptinezumab compared with placebo as published previously; however, these outcomes do not fully capture the burden of migraine and treatment effect. Methods PROMISE‐2 was a phase 3, randomized, double‐blind, placebo‐controlled trial in adults with CM. Patients were randomized (1:1:1) to receive eptinezumab 100 mg, eptinezumab 300 mg, or placebo (up to 2 doses, 12 weeks apart). Patients completed the following patient‐reported outcomes: 6‐item Headache Impact Test (HIT‐6), Patient Global Impression of Change (PGIC), patient‐identified most bothersome symptom (PI‐MBS), and 36‐item Short‐Form Health Survey (SF‐36). Results A total of 431 CM patients (139, 147, and 145 patients in the eptinezumab 100 mg, eptinezumab 300 mg, and placebo groups, respectively) had MOH diagnosed at screening (40.2% of the total PROMISE‐2 population [ n = 1072]). In CM with MOH patients, both doses of eptinezumab were associated with clinically meaningful improvements in mean HIT‐6 total scores by week 4 and remained improved throughout the 24‐week study. Responder rates for individual HIT‐6 items were greater with eptinezumab than with placebo at all time points. At week 12, almost twice as many eptinezumab‐treated patients indicated the PGIC was “much” or “very much” improved (58.5% [79/135, 100 mg] and 67.4% [95/147, 300 mg] vs. 35.8% [48/134, placebo]). Patients in the eptinezumab groups showed numerically greater improvements over placebo in the PI‐MBS and SF‐36 scores. Conclusions This subgroup analysis in patients with CM/MOH at baseline suggests that eptinezumab treatment is associated with early, sustained, and clinically meaningful improvements in patient‐reported outcomes.
CPD providers can positively impact practice by better understanding how APNs are educated, licenced, and certified
Davidson-Corbett, DeeAnn, Godwin, Cherith, McNeely, Heidi L. , Ramirez, Jeffery , Smith, J.M. , Smith, Justin , Smith, Justin

Mayo Clinic

Journal of CME | January 12, 2023 | Volume: 12 | Issue: 1 | Pages: No page available

10.1080/28338073.2022.2160531 | PMID 36969487 Get It

Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase
Martin, Catherine E. , Kohorst, Mira A. , Kalmes, Jessica, Galardy, Paul J. , Khan, Shakila P. , Kuhn, Alexis , Kalmes, Jessica L., Johnson, Heather M. , Galardy, Paul J , Kuhn, Alexis K , DeFino, Catherine E. , Ferdjallah, Asmaa , Johnson, Heather M.

Mayo Clinic

Pediatric Blood & Cancer | January 12, 2023 | Volume: 70 | Issue: 5 | Pages: No page available

10.1002/pbc.30208 | PMID 36633209 Get It

Initial safety outcomes for the Rigicon Infla10® inflatable penile prosthesis
Wilson, Steven K. , Wen, Lexiaochuan , Rossello, Mariano, Maria, Pedro , Carrion, Rafael , Perito, Paul , Ralph, David , Carvajal, Alejandro , Chung, Eric , Antonini, Gabriele , Ozturk, Metin Ishak

Mayo Clinic

BJU International | January 12, 2023 | Volume: 131 | Issue: 6 | Pages: 729-733

10.1111/bju.15960 | PMID 36633050 Get It

Objective To analyse data from patient information forms (PIFs) submitted to the manufacturer of a new three‐piece inflatable penile prosthesis (IPP), the Rigicon Infla10®, to summarize early outcomes. Methods A retrospective review of PIFs from 319 patients implanted with the IPP between 6 January 2019 and 31 December 2021 was performed to assess device durability and rates of reoperation for infection, mechanical failure or medical reasons. Results The mean ± sd (range) follow‐up was 21.2 ± 11 (5–36) months and the mean ± sd patient age was 58.5 ± 8.7 years. Of the total, 4.4% of devices required removal or revision. Complications included mechanical failure (2.5%) and component migration (0.7%). No infections were observed in this series. One patient (0.4%) required revision for inadequate straightening of Peyronie's disease. Three patients (0.9%) requested device removal because of dissatisfaction. A total of 95.6% of the Rigicon Infla10 devices were free from explant or revision 21 months after the original implant date. Kaplan–Meier analysis showed the rates of cumulative survival of the device at 12, 24, 36 months were 95.6%, 94.7% and 93.7%, respectively. Conclusions The vast majority of the early Rigicon Infla10 IPPs implanted prior to January 2022 were included in this retrospective analysis of volunteered PIFs. These early results demonstrate initial durability from reoperation equivalent to that of other contemporary devices.
Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study
Núñez, Nicolás A. , Kumar, Rakesh , Pahwa, Mehak , Ercis, Mete , Özerdem, Ayşegül , Stan, Marius N. , Frye, Mark A. , Singh, Balwinder , Joseph, Boney , Pazdernik, Vanessa , Kumar, Rakesh , Ercis, Mete , Stan, Marius N , Singh, Balwinder , Ozerdem, Aysegul , Joseph, Boney , Cuéllar‐Barboza, Alfredo B. , Romo‐Nava, Francisco , McElroy, Susan L. , Coombes, Brandon J. , Biernacka, Joanna M.

Mayo Clinic

Brain Sciences | January 12, 2023 | Volume: 13 | Issue: 1 | Pages: 133

10.3390/brainsci13010133 | PMID 36672114 Get It

Lithium has been a cornerstone treatment for bipolar disorder (BD). Despite descriptions in the literature regarding associations between long-term lithium therapy (LTLT) and development of a thyroid disorder (overt/subclinical hypo/hyperthyroidism, thyroid nodule, and goiter) in BD, factors such as time to onset of thyroid abnormalities and impact on clinical outcomes in the course of illness have not been fully characterized. In this study we aimed to compare clinical characteristics of adult BD patients with and without thyroid disorders who were on LTLT. We aimed to identify the incidence of thyroid disorders in patients with BD on LTLT and response to lithium between patients with and without thyroid disorders in BD. The Cox proportional model was used to find the median time to the development of a thyroid disorder. Our results showed that up to 32% of patients with BD on LTLT developed a thyroid disorder, of which 79% developed hypothyroidism, which was corrected with thyroid hormone replacement. We did not find significant differences in lithium response between patients with or without thyroid disorders in BD. Findings from this study suggest that patients with BD and comorbid thyroid disorders when adequately treated have a response to lithium similar to patients with BD and no thyroid disorders.
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
Dutta, Navnita , Han, Bing , Ciccio, Gina , Cherukuri, Yesesri , Alegria, Victoria R., LaPlant, Betsy, Sher, Taimur , Lanier, Stephanie, Manna, Alak , Heslop, Keisha, Caulfield, Thomas R. , Maldosevic, Emir , Störz, Peter , Asmann, Yan W. , Chanan‐Khan, Asher , Paulus, Aneel , Dutta, Navnita , Han, Bing , LaPlant, Betsy R, Edwards, Brett , Caulfield, Thomas R , Storz, Peter , Asmann, Yan, Chanan-Khan, Asher A., Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Roy, Vivek , Edwards, Brett, Manochakian, Rami

Mayo Clinic

Cancers | January 12, 2023 | Volume: 15 | Issue: 2 | Pages: 477

10.3390/cancers15020477 | PMID 36672426 Get It

Bcl-2 and Mcl-1 proteins play a role in multiple myeloma (MM) cell survival, for which targeted inhibitors are being developed. AT-101 is an oral drug, which disrupts Bcl-2 and Mcl-1 function, impedes mitochondrial bioenergetic processes and induces apoptosis in MM cells. When combined with lenalidomide and dexamethasone (Rd), AT-101 significantly reduced tumor burden in an in vivo xenograft model of MM. These data provided rationale for a phase I/II study to establish the effective dose of AT-101 in combination with Rd (ARd regimen) in relapsed/refractory MM. A total of 10 patients were enrolled, most with high-risk cytogenetics (80%) and prior stem cell transplant (70%). Three patients were lenalidomide-refractory, 2 were bortezomib-refractory and 3 were daratumumab-refractory. The ARd combination was well tolerated with most common grade 3/4 adverse events being cytopenia’s. The overall response rate was 40% and clinical benefit rate was 90%. The median progression free survival was 14.9 months (95% CI 7.1-NE). Patients responsive to ARd showed a decrease in Bcl-2:Bim or Mcl-1:Noxa protein complexes, increased CD8+ T and NK cells and depletion of T and B-regulatory cells. The ARd regimen demonstrated an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM prompting further investigation in additional patients.